Week of June 20, 2016
Recruitment
On behalf of Dr. Takaji Kittaka, CMO we are very excited to announce that Dr. Jose DeJesus has signed an employment contract for the Adena Jackson Family Practice clinic. Dr. DeJesus graduated from Adena’s Family Practice Residency on 06/23/2016. He will finish his training in December of 2016 and start in Jackson in January 2017. Dr. DeJesus performed his Medicine training at West Virginia School of Osteopathic Medicine and his residency at our very own Adena Residency training program. Please welcome Dr. DeJesus as a new attending family practice physician for Adena Family Practice. We are ecstatic Dr. DeJesus choose Adena’s caregiver team!
Meditech Ambulatory Project
The Meditech 6.15 Ambulatory application go-live date of October 3, 2016 has been postponed along with related PTO black-out dates.
While there has been progress there are key open tasks impacting the ability to successfully plan a go-live. A punch list of key tasks has been compiled and will be used to determine go-live readiness. For those clinics in the first wave, a minimum 90 day go-live notice will be provided.Based on the punch list of required tasks and Q4 2016 holidays, the go-live window would open in late February 2017 with an expectation the Ambulatory conversion would be complete by the end of 2017.
ACIP Advises Against Using LAIV For Upcoming Influenza Season – on behalf of Fred Yingling, Director, Pharmacy
The CBS Evening News (6/23, story 10, 0:15, Pelley) reported that a Centers for Disease Control and Prevention panel “has reversed itself, saying that there is no evidence that FluMist works.”
The New York Times (6/23, Bakalar) reports that the CDC’s Advisory Committee on Immunization Practices concluded that “the nasal flu vaccine spray, preferred by millions of anxious parents looking for a needle-free way to get their children immunized against the flu, as well as by adults who would rather not get a flu shot, is ineffective and should not be used in the upcoming flu season.”
MedPage Today (6/23, Walker) reports that the Centers for Disease Control and Prevention’s Committee of Immunization Practices voted 13-1 to recommend that “live attenuated influenza vaccine (LAIV, sold as FluMist Quadrivalent) should not be used for the 2016-2017 influenza season.” According to the committee, the evidence indicated “poor effectiveness of LAIV in the U.S. over the last three influenza seasons.” Instead, the “inactivated influenza vaccine or recombinant influenza vaccine will be used for all individuals ages ≥6 months this coming influenza season.”
Medscape (6/23, Brown) reports that data showed that during last influenza season, “LAIV vaccine effectiveness against any influenza virus among children aged 2 through 17 years was only 3% (95% confidence interval, −49% to 37%) compared with 63% (95% confidence interval, 52% – 72%) for IIV.”
US News & World Report (6/23, Dicker) reports that AstraZeneca, which owns the company that makes FluMist, “disputed the CDC’s findings,” arguing that the CDC’s findings contradict their internal data, “which shows that FluMist was 46 percent to 58 percent effective against flu this past year.”
The Washington Post (6/23, Sun) reports that according to the CDC, “the needle-free nasal spray accounts for about one-third of all flu vaccines given to children.” Manufacturers “had projected that as many as 171 million to 176 million doses of flu vaccine, in all forms, would be available for the United States during the coming flu season,” with the “makers of the nasal spray had projected a supply of as many as 14 million doses, or about 8 percent of the total projected supply.”
Additional coverage is provided by TIME (6/23, Sifferlin) and NPR (6/23, Beans).
Population Health
Population Health is taking a forward approach to increase Diabetic compliance by assisting patients with lowering their A1C and completing yearly Diabetic eye and foot exams. In last week’s CMO newsletter, Adena Care educated providers on the Diabetic metric goals and the importance of encouraging patients to have the recommended lab work and testing.
Dr. Jennifer Davis and her team have agreed to champion a pilot program focusing on high and priority risk Diabetic patients. The M.A. will identify care gap opportunities at the time of the visit by utilizing a Qlikview Diabetic work list. If a patient has not completed their A1C, Micro albumin, eye or foot exam as outlined in the Diabetes Care Guidelines then the M. A. will notify Dr. Davis prior to entering the room. If appropriate, testing can be ordered before the patient leaves the office.
Team based care has proven to be an effective approach in managing a patient’s chronic disease process. The identification of Diabetic care gap opportunities during the patient visit enables the provider to order necessary labs and screenings therefore promoting the health of our patients.
We look forward to working with Dr. Davis and her team as we continue to promote the health of our Diabetic population.
Save the date
Mark your calendar for Thursday, Sept. 1, 2016 for the annual AMG Provider Wine Meet and Greet. This is a fun, networking event to give all Medical Staff the opportunity to meet new providers. The event will be held at the Pump House, located in Yoctangee Park.More information to come soon from Faitha Shelton, Physician HR Director.
Reminder - Provider Portal
Please remember to check out the Provider Portal at www.adena.org/physicianportal and stay up-to-date on the latest information and events happening within Adena. The portal is also a way we hope to further communication between providers. We intend to continue to enhance the portal as we strive to improve communication to and with each other.
Inpatient Clinical Documentation Integrity (CDI)Reminder
Bacteremia, when coded goes to the signs and symptoms DRG, and should not be used as the principle diagnosis if an alternative diagnosis exists. Bacteremia just denotes a finding of bacteria in the blood and does not specify an infectious process.
Wayne
Tony
Takaji